119 - Treatment Conundrums: Not Always Black and White

Friday, October 18, 2024

10:30 AM – 11:45 AM US PT

Location: Concourse 151

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Pranita Tamma, MD, MHS

Associate Professor
Johns Hopkins School of Medicine
Baltimore, MD, United States
Kathleen Chiotos, MD, MSCE (she/her/hers)

Assistant Professor
Children's Hospital of Philadelphia
Philadelphia, PA, United States

Faculty(s)

Navaneeth Narayanan, PharmD, MPH, BCIDP

Clinical Associate Professor & Infectious Diseases Pharmacist
Rutgers University Ernest Mario School of Pharmacy & Robert Wood Johnson University Hospital
New Brunswick, NJ, United States
Sarah Doernberg, MD, MAS (she/her/hers)

Professor
University of California, San Francisco
San Francisco, CA, United States
Kate DeSear, PharmD, BCIDP, AAHIVP, FIDSA (she/her/hers)

Clinical Infectious Diseases Pharmacist
UF Health Shands Hospital
Gainesville, FL, United States

Disclosure(s):

Pranita Tamma, MD, MHS: No financial relationships to disclose

Kathleen Chiotos, MD, MSCE: No financial relationships to disclose

Navaneeth Narayanan, PharmD, MPH, BCIDP: Astellas: Honoraria (); Beckman Coulter: Honoraria (); Merck: Grant/Research Support (); Shionogi: Grant/Research Support ()

Sarah B. Doernberg, MD, MAS: Basilea Pharmaceutica: Grant/Research Support; F2G Limited: Grant/Research Support; Genentech: Advisor/Consultant; Gilead Biosciences: Grant/Research Support; Janssen/J+J: Advisor/Consultant; Pfizer, Inc: Grant/Research Support; Regeneron, Inc: Grant/Research Support; Shinogi: Grant/Research Support

Kate DeSear, PharmD, BCIDP, AAHIVP, FIDSA: AbbVie Inc: Advisor/Consultant (Terminated, May 10, 2024); Basilea Pharmaceutica: Advisor/Consultant (Terminated, July 1, 2023); GSK: Advisor/Consultant (Terminated, January 8, 2024); La Jolla (Entasis): Advisor/Consultant (Terminated, July 1, 2023); Melinta Therapuetics: Advisor/Consultant (Terminated, June 21, 2023)

Learning Objectives:

At the conclusion of this session, participants will be able to:

determine if aminopenicillins remain a treatment option for ampicillin-resistant enterococcus urinary tract infections;
recognize antibiotic treatment strategies for diabetic foot infections;
identify the potential for acute kidney injury with piperacillin-tazobactam and vancomycin.

Presentations:

10:30 AM – 10:55 AM US PT

Aminopenicillins: Are they still a treatment option for ampicillin-resistant Enterococcus urinary tract infections?
Speaker: Navaneeth Narayanan, PharmD, MPH, BCIDP – Rutgers University Ernest Mario School of Pharmacy & Robert Wood Johnson University Hospital
10:55 AM – 11:20 AM US PT

How should I select antibiotic agents for the treatment of diabetic foot infections?
Speaker: Sarah B. Doernberg, MD, MAS (she/her/hers) – University of California, San Francisco
11:20 AM – 11:45 AM US PT

Should I avoid piperacillin, tazobactam and vancomycin for patients at risk for acute kidney injury?
Speaker: Kate DeSear, PharmD, BCIDP, AAHIVP, FIDSA (she/her/hers) – UF Health Shands Hospital